As we step into 2022 with immense optimism for a better future, I am glad to connect with you through this December 2021 edition of Oviya MedSafe’s newsletter (the 111th in the series since April 2012) in which I wish to share with you some noteworthy appreciations from our new clients in 2021.
The year 2021 was phenomenal for Oviya MedSafe as it brought to us a wide variety of Pharmacovigilance projects with most of them being overseas assignments. Although versatility is not new to Oviya MedSafe, the leagues of clients that we worked with in 2021 and the symbiotic business relationships we built with them in the process have assured us that much bigger achievements are in store for us in 2022 and beyond. Another rewarding aspect we noted in 2021 was that most of such clients, regardless of whether they were innovators or generic pharma, did not hesitate to sign long-term contracts with us even though their products were quite early in the life cycle, thereby confirming their trust in Oviya MedSafe as a reliable global Pharmacovigilance partner.
One of such clients is an emerging Marketing Authorisation (MA) Holder in the United Kingdom (UK) whom we have been assisting with all their Pharmacovigilance requirements right from the dossier preparation stage, including UK Qualified Person for Pharmacovigilance (QPPV) support. Having grown organically over the past decade, Oviya MedSafe is very well-positioned to understand the challenges of a self-funded start-up and proposed a flexible long-term financial model which ensured little burden on the client during their fledgling stages. With their MA approvals round the corner, the client now happily looks forward to do further business with Oviya MedSafe.
On the other side of the spectrum, Oviya MedSafe was chosen by a large & leading
multinational healthcare products company to set up a corporate Pharmacovigilance system and integrate it with their established Medical Information department in order to achieve total regulatory compliance. What started with a multipronged approach comprising of consulting, training and auditing elements, culminated in a holistic Patient Safety Practice in the organization. We are all set to begin running their global Pharmacovigilance system on their behalf shortly. Here also, our novel approaches resulted in deep-seated satisfaction for the client as well as ourselves.
From the above two representative samples, what I intend to highlight is that we have succeeded in our endeavours not just because of our rich expertise in the domain but also because we have the ability to customize our offerings to address the specific business challenges of each client in a cost-effective manner. While this does sound to be a logical strategy that any prudent business house will adopt, I believe such ideas would flow in only when we are passionate about what we do and also work with an efficient team that enjoys solving such problems, just as what we are and have at Oviya MedSafe 😊
To quote the words of the great visionary philanthropic ophthalmologist of India Dr
Govindappa Venkataswamy (Dr V), “Intelligence and capability are not enough. There must be the joy of doing something beautiful.”
Moving on to my personal pursuits in Pharmacovigilance, I am pleased to share with you a video recording of my invited interactive short lecture at CIMACON 2021 (the annual State Medical Conference of the Indian Medical Association Tamil Nadu State Branch) at Coimbatore on 11th Dec 2021. While my original talk had been titled “Pharmacovigilance & Drug Safety – An Introduction”, I now feel it could have been better with the title “Adopting Pharmacovigilance in Clinical Practice”, as the audience was full of practising doctors for whom ‘Pharmacovigilance’ was not a familiar term. Low audio volume is regretted as it was so in the source. Please use headphones/earphones for better experience. And, do feel free to share this video with your network if you like it!
Last but not the least; the month was quite special to me in an individual capacity, as the Pharmacovigilance Special Section of Global Forum, for which DIA chose me as the Special Section Editor, was first published in the December 2021 issue. With the January 2022 issue also out now, I am sure you will benefit a lot by reading the curated articles focused on innovations in Pharmacovigilance and authored by seasoned experts in the subject from many parts of the world. Of course, more is to come in the February 2022 issue as well. I take this occasion to thank DIA editorial team once again for having given this privilege of an opportunity to me.
Wishing you all Happy Pongal/Makar Sankranti/Lohri/Uttarayan/Magh Bihu and related festivities,
Keen to meet you in our January 2022 newsletter,
With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA, FPIPA (UK)
Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Oviya MedSafe UK Ltd,